These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37712156)

  • 1. [SGLT2 inhibitors : on the borders of diabetology, cardiology, nephrology and… primary care].
    Scheen A; Lancellotti P; Delanaye P; Giet D
    Rev Med Liege; 2023 Sep; 78(9):476-483. PubMed ID: 37712156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SGLT2 inhibitors and RAAS blockers : similarities, differences and complementarity].
    Scheen AJ; Delanaye P
    Rev Med Liege; 2022 Jan; 77(1):18-24. PubMed ID: 35029336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease.
    Scheen AJ; Delanaye P
    Expert Rev Endocrinol Metab; 2022 Jan; 17(1):35-46. PubMed ID: 34908510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.
    Scheen AJ
    Expert Rev Endocrinol Metab; 2023; 18(4):271-282. PubMed ID: 37154218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice].
    Scheen AJ; Delanaye P
    Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [SGLT2 inhibitors, new option to prevent or treat heart failure].
    Scheen AJ; Lancellotti P
    Rev Med Liege; 2021 Apr; 76(4):248-255. PubMed ID: 33830688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors].
    Valdes-Socin H; Scheen AJ; Jouret F; Grosch S; Delanaye P
    Rev Med Liege; 2022 Mar; 77(3):175-180. PubMed ID: 35258866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dapagliflozin in DELIVER : confirmation of the benefit with SGLT2 inhibitors in heart failure with preserved ejection fraction].
    Scheen A; Lancellotti P
    Rev Med Liege; 2023 Feb; 78(2):79-84. PubMed ID: 36799324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.
    de Pouvourville G; Rossignol P; Boussahoua M; Chevalier J; Gabb PD; Poulnais R; Verboux D; Rao N; Sörstadius E; Garcia Sanchez JJ
    Adv Ther; 2023 Sep; 40(9):3751-3769. PubMed ID: 37341914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Herrington WG; Savarese G; Haynes R; Marx N; Mellbin L; Lund LH; Dendale P; Seferovic P; Rosano G; Staplin N; Baigent C; Cosentino F
    Eur J Heart Fail; 2021 Aug; 23(8):1260-1275. PubMed ID: 34184823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [SGLT2 inhibitors for heart and kidney].
    van der Giet M
    Dtsch Med Wochenschr; 2023 Nov; 148(22):1456-1461. PubMed ID: 37918431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular benefit of SGLT2 inhibitors.
    Mohebi R; Januzzi JL
    Crit Rev Clin Lab Sci; 2022 May; 59(3):142-155. PubMed ID: 34784839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.
    Kovesdy C; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Fried L
    BMC Med; 2022 Jan; 20(1):2. PubMed ID: 35000594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
    Benvenuto M; Panzarella G; Shehaj E; Valenti C; Caldarola P; Colivicchi F; Gabrielli D; Iacoviello M;
    G Ital Cardiol (Rome); 2023 Mar; 24(3):188-195. PubMed ID: 36853155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.